LBX Pharmacy Chain Joint Stock (603883) Fundamentals 2026 — P/E 23.7x, Revenue Analysis | SniperIQ
LBX Pharmacy Chain Joint Stock (603883) is a CN-listed Healthcare company in Medical - Pharmaceuticals with a market capitalization of ¥9.3B, trading at ¥12.30 on the SHH. This SniperIQ fundamentals page covers LBX Pharmacy Chain Joint Stock's valuation (P/E 23.7x, P/B 1.4x), profitability (net margin 1.8%), revenue (¥22.2B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is LBX Pharmacy Chain Joint Stock's market cap?
LBX Pharmacy Chain Joint Stock (603883) has a market capitalization of approximately ¥9.3B, trading at ¥12.30 on the SHH. Market cap moves with the live share price.
What is LBX Pharmacy Chain Joint Stock's P/E ratio?
LBX Pharmacy Chain Joint Stock's trailing twelve-month P/E ratio is 23.7x, with a price-to-book (P/B) of 1.4x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is LBX Pharmacy Chain Joint Stock?
LBX Pharmacy Chain Joint Stock runs a net profit margin of 1.8%, a gross margin of 32.1%, and an operating margin of 5.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does LBX Pharmacy Chain Joint Stock generate?
LBX Pharmacy Chain Joint Stock reported revenue of ¥22.2B for fiscal year 2025, with net income of ¥382M and earnings per share (EPS) of 0.5. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does LBX Pharmacy Chain Joint Stock pay a dividend?
LBX Pharmacy Chain Joint Stock offers a trailing dividend yield of about 3.3%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is LBX Pharmacy Chain Joint Stock financially healthy?
LBX Pharmacy Chain Joint Stock carries a debt-to-equity ratio of 0.44x and a current ratio of 0.90x, with a market beta of 0.55. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is LBX Pharmacy Chain Joint Stock a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For LBX Pharmacy Chain Joint Stock (603883) the key facts are: market cap ¥9.3B, P/E 23.7x, revenue ¥22.2B, 52-week range 10.67-20.03. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track LBX Pharmacy Chain Joint Stock's full fundamentals live
Get LBX Pharmacy Chain Joint Stock's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.